The late-stage human trial showed a median survival increase of 2.7 months compared with patients who received chemotherapy alone.

FORBES: Magazine Article

Dr. Scher reported that the 800 patients treated with the drug had a median survival of 18.4 months compared with 13.6 months for those given a placebo.

WSJ: New Medical Strides Against Prostate Cancer

In sum, Frovenge provides a median survival benefit somewhere in magnitude between 0 and 10 months, which implies that Provenge provides a median survival benefit somewhere in the range of 4-14 months.

FORBES: Why The New Dendreon Analysis Does Matter -- And Why It Doesn't

One of the trials, IMPACT, was formally re-engineered, showed a four-month median survival benefit for Provenge, and was published in the New England Journal of Medicine.

FORBES: Dendreon Data Are Merely Moderate, But Stock Surges Anyway

Median survival without a worsening of tumors increased to 18.5 months.

WSJ: Breast-Cancer Drugs Raise Hopes

Even with chemotherapy, the median survival is about a year.

NEWYORKER: Letting Go

As in late-stage colon cancer, overall median survival was extended by only a few months.

FORBES: Genentech's Rite Of Spring

's aromatase inhibitor Aromasin, it improved survival without tumor growth to a median 7.4 months, compared with Aromasin alone.

WSJ: Breast-Cancer Drugs Raise Hopes

Gould, of course, ignored this advice and soon discovered that the median survival for patients with this diagnosis was a mere 8 months.

FORBES: Do Oncologists Lie to Their Patients About Their Prognoses?

Gliadel extends the median survival by six weeks, and then only for patients hardy enough to have withstood a second surgery.

FORBES: Taking on a Monster